11 Flabra, frontline approach for BRCA testing in ovarian cancer (OC) treatment naïve population. A latin america (LA) epidemiologic study. (18th September 2019)

• Record Type: Journal Article
• Authors: Goncalves, S; Gomez Abuin, G; Gallardo, D; Estevez Diz, P; Caceres, V; De la Vega, M; Palazzo, F; Lerzo, G; Kaen, D; Gerson, R; Lim, M; Philco, M; Moreira Costa Zorzzeto, M; De Melo, AC; Hegg, R; de Oliveira Santana, R; Medeiros Milhomen Beato, P; Trujillo, L; Plata, M; Yepes, A; Cock, A; Bonifacino, MM; Cortes, M; Fein, L; Castillo, C; Pacheco, C; Ticona, M; Hoyoa, E; Jaramillo, R; Soare Nunes, J; Menezes Morelle, A; Freire de Carvalho Calabrich, A; Cronemberger Costa e Silva, EH; Mora, P; Damian, F; Diaz Perez, I; Sganga, L; Pereira, MH; Ramirez, H; Nogueira, A; Guindalini, R; Miranda, V; Giornelli, G;
• Is Part Of: International journal of gynecological cancer. Volume 29(2019)Supplement 3
• Page Start: A7
• Page End: A7
• Publication Date: 2019-09-18
• Subjects: Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1136/ijgc-2019-IGCS.11
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : Objectives: Previously described prevalence of BRCA mutated OC is 14% for germline BRCA mutations (gBRCA M ), that could increase to 20% considering somatic BRCA mutations (sBRCA M ). Latinamerican population is a paradigm of poly-ethnicity and ancestries and the prevalence of BRCAm is unknown. FLABRA is a cross-sectional, multi-center study designed to determine the prevalence of BRCAm, either sBRCA M or gBRCA M in high grade serous OC LA patients, with a new approach of start testing in tumor. We also aimed to describe current genetic counselling and treatment approach at frontline in this population. Methods: We enrolled 407 patients from Argentina, Brazil, Colombia, Mexico, Peru and Panama, diagnosed with OC within the last 120 days. Archived tumor blocks or 10-µm sections were used for BRCA testing in tissue (Myriad Tumor BRACAnalysis CDx™). Patients who were positive in tumor, were analysed in blood to determine if the mutation was from germline (Myriad Single Site BRACAnalysis®). In gBRCA M, genetic counseling was advised. Patients medical records were reviewed for data relevant to medical history, OC diagnosis, counseling approach, and treatment plan. Results: Results from first 376 patients who already completed the study: BRCA mutations prevalence detected in tumor was 30%. Conclusions: Our data show a high prevalence of sBRCAM and gBRCAM in LA OC pts. Additionally, this new approach of start testing the tumor may prove to be more cost effective, leading to a more conclusive result; so refinement of this technique is a must. The high prevalence of sBRCAM in certain regions of LA needs to be further investigated.